Search
Now showing items 1-1 of 1
New clinical approaches and emerging evidence on immune-checkpoint inhibitors as anti-cancer therapeutics: CTLA-4 and PD-1 pathways and beyond
(
Begell House Inc.
, 2019 , Article)
The development of immune checkpoint blockers, primarily comprising the anti-PD-1/anti-PD-L1 and anti-CTLA-4 monoclonal antibodies, has formed the therapeutic landscape of quite a few different cancer types. In spite of ...